Our results show that the modifications induced by the pretreatment of LB1319-MEL melanoma cells with hIFN-γ and GGTI-298 promote an anti-tumor immune response by increasing the number of specific CD8 T lymphocytes labeled with MART-1/HLA-A2 tetramers. This evidence concerns the gene PGGT1B and melanoma.